目的 探討還原型谷胱甘肽聯(lián)合甘草酸二銨治療非酒精性脂肪肝的臨床療效。方法 選擇2017年3月—2019年3月在南通大學(xué)附屬如皋醫(yī)院治療的120例非酒精性脂肪性肝病患者，隨機分為對照組和治療組，每組各60例。對照組口服甘草酸二銨腸溶膠囊，150 mg/次，3次/d。治療組在對照組基礎(chǔ)上肌肉注射注射用還原型谷胱甘肽，2支/d。兩組患者均治療12周。觀察兩組患者臨床療效，比較治療前后兩組患者谷氨酸氨基轉(zhuǎn)移酶（AST）、丙氨酸氨基轉(zhuǎn)移酶（ALT）、總膽固醇（TC）、低密度脂蛋白（LDL-C）、高密度脂蛋白（HDL-C）、三酰甘油（TG）、谷胱甘肽過氧化物酶（GSH-Px）、超氧化物歧化酶（SOD）和丙二醛（MDA）水平。結(jié)果 治療后，治療組臨床有效率（93.33%）明顯高于對照組（79.66%，P＜0.05）。治療后，兩組AST、ALT、TC、TG、LDL-C和MDA水平均較治療前明顯下降，而HDL-C、GSH-Px和SOD水平明顯升高（P＜0.05），且治療組這些指標(biāo)水平明顯好于對照組（P＜0.05）。結(jié)論 還原型谷胱甘肽聯(lián)合甘草酸二銨治療非酒精性脂肪肝病的療效明顯。

Objective To investigate the curative effect of reduced glutathione combined with diammonium glycyrrhizinate in treatment of non-alcoholic fatty liver. Methods Patients (120 cases) with non-alcoholic fatty liver in Rugao Hospital Affiliated to Nantong University from March 2017 to March 2019 randomly were divided into control and treatment group, and each group had 60 cases. Patients in the control group was po administered with Diammonium Glycyrrhizinate Enteric-coated Capsules, 150 mg/time, three times daily. Patients in the treatment group were im administered with Reduced Glutathione for injection on the basis of the control group, 2 injections/d. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluation was evaluated, and the levels of AST, ALT, TC, TG, LDL-C, HDL-C, GSH-Px, SOD, and MDA in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (93.33%) was significantly higher than that of the control group (79.66%, P < 0.05). After treatment, the levels of AST, ALT, TC, TG, LDL-C, and MDA in two groups were significantly lower than those before treatment, while the levels of HDL-C, GSH-Px, and SOD were significantly increased (P < 0.05), and these indexes level in the treatment group was significantly better than that in the control group (P < 0.05). Conclusion Reduced glutathione combined with diammonium glycyrrhizinate is effective in treating non-alcoholic fatty liver non-alcoholic fatty liver disease.

R975